Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: A preliminary study

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 1, 2005, Pages 75-84

  Kook, Michael S ^a   Cho, Hyun Soo ^a   Yang, Sung Jae ^a   Kim, Suhyun ^b   Chung, Jiyong ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARTEOLOL; DORZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL;

ADULT; AGED; ANTERIOR EYE CHAMBER ANGLE; ARTICLE; BIOMICROSCOPY; CHRONIC DISEASE; CILIARY BODY; CLINICAL ARTICLE; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA EROSION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EYE IRRITATION; EYE SYNECHIA; FEMALE; GONIOSCOPY; HUMAN; INTRAOCULAR PRESSURE; IRIS; MALE; SIDE EFFECT; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

EID: 14044253514     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.75     Document Type: Article

References (24)

1. Alm, A., Widengard, I., Kjellgren, D., et al. Latanoprost administered once-daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br. J. Ophthalmol. 79:12-16, 1995.
2. Alm, A., and Stjernschantz, J. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once-daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752, 1995.
3. Camras, C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138-147, 1996.
4. Watson, P., and Stjernschantz, J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126-137, 1996.
5. Mishima, H.K., Masuda, K., Kitazawa, Y., et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and oclar hypertension. A 12-week study. Arch. Ophthalmol. 114:929-932, 1996.
6. Camras, C.B., Alm, A., Watson, P., et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. The Latanoprost Study Groups. Ophthalmology 103:1916-1924, 1996.
7. Watson, P.G. Latanoprost. Two years' experience of its use in the United Kingdom. The Latanoprost Study Group. Ophthalmology 105:82-87, 1998.
8. Rulo, A.H., Greve, E.L., Geijssen, H.C., et al. Reduction of intraocular pressure with treatment of latanoprost once-daily in patients with normal-pressure glaucoma. Ophthalmology 103:1276-1282, 1996.
9. Lindsey, J.D., Kashiwagi, K., Kashiwagi, F., et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest. Ophthalmol. Vis. Sci. 38:2214-2223, 1997.
10. 2α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 117:794-801, 1999.
11. Aung, T., Wong, H.T., Yip, C.C., et al. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: A preliminary study. Ophthalmology 107:1178-1183, 2000.
12. Wilensky, J.T., Gandhi, N., and Pan, T. Racial influences in open-angle glaucoma. Ann. Ophthalmol. 10:1398-1402, 1978.
13. Chew, P.T., Aung, T., Aquino, M.V., et al. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology 111:427-434, 2004.
14. Pavlin, C.J., and Foster, F.S. Anterior segment tumors. In: Ultrasound Biomicroscopy of the Eye. New York: Springer-Verlag, 1995:98-139.
15. 2. Fortschr. Ophthalmol. 87:623-629, 1990.
16. Lindsey, J.D., Kashiwagi, K., Boyle, D., et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth-muscle cells. Curr. Eye Res. 15:869-875, 1996.
17. Weinreb, R.N., Kashiwagi, K., Kashiwagi, F., et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth-muscle cells. Invest. Ophthalmol. Vis. Sci. 38:2772-2780, 1997.
18. Matrisian, L.M. The matrix-degrading metalloproteinases. Bioessays 14:455-463, 1992.
19. Nagase, H., and Okada, Y. Proteinases and matrix degradation. In Kelly JWN, Ruddy S, Sledge C, eds., Textbook of Rheumatology, Philadelphia: W.B. Saunders Co., 1997:323-341.
20. Gaton, D.D., Sagara, T., Lindsey, J.D., et al. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest. Ophthalmol. Vis. Sci. 40:363-369, 1999.
21. Gaton, D.D., Sagara, T., Lindsey, J.D., et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F (2 alpha)-isopropyl ester treatment. Arch. Ophthalmol. 119:1165-1170, 2001.
22. Dinslage, S., Hueber, A., Kiestelhorst, M., et al. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: A double-masked, placebo-controlled clinical study. Graefe's Arch. Clin. Exp. Ophthalmol. 242:654-660, 2004.
23. 2α receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 39:315-321, 1998.
24. 2 alpha analog, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1351-1358, 1993.